Terazosine and tamsulosin in non bacterial prostatitis: a randomized placebo-controlled study.

Abstract

Eighteen patients with inflammatory process of the prostate met criteria for the inclusion in the study: 1) non bacterial prostatitis; 2) no previous treatment. Then they were randomized into three groups as it follows: terazosine, tamsulosin and placebo. Alpha-blockers and placebo were given for two months, after which further uroflowmetry was performed. Symptom score was evaluated before and after treatment. Terazosine was effective in reducing TO (p = 0.01) as tamsulosin and placebo did not. Both terazosine (p = 0.034) and tamsulosin (p = 0.006) reduced max TQ as placebo did not. Symptom score significantly improved in patients receiving terazosine (p = 0.0002) and tamsulosin (p = 0.001) while insignificantly in whose receiving placebo.

• Authors: S Lacquaniti, A Destito, C Servello, M O Candidi, J M Weir, G Brisinda, E Alcini
• Journal: Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica (Arch Ital Urol Androl) Vol. 71 Issue 5 Pg. 283-5 (Dec 1999) ISSN: 1124-3562 [Print] Italy
• PMID: 10673791 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Adrenergic alpha-Antagonists
• Sulfonamides
• Terazosin
• Tamsulosin
• Prazosin

Topics

• Adrenergic alpha-Antagonists (therapeutic use)
• Adult
• Humans
• Male
• Prazosin (analogs & derivatives, therapeutic use)
• Prospective Studies
• Prostatitis (drug therapy)
• Sulfonamides (therapeutic use)
• Tamsulosin